Complete disappearance of all detectable clin ical evidence of disease and disease-related symptoms, if present before therapy. Revised Protocol No.: 04 Date: 31-May-2019 189 Approved 5.0 v Approved 1.0 v Clinical Protocol CA021002 BMS-986226 anti-ICOS a) Typically FDG-avid lymphoma: in patients wit hout a pre-treatment PET scan or if the pre-treatment PET scan was positive, a post-treatment residual mass of any size is permitted as long as it is PET negative. b) Variably FDG-avid lymphomas/FDG avidity unknown: in patients without a pre-tr eatment PET scan, or if a pre-treatment PET scan was negative, all lymph nodes and nodal masses must have regressed on CT scan to normal s ize (≤1.5 cm in their greatest transverse diameter for nodes > 1.5 cm before therapy). Previously involved nodes that were 1.1 to 1.5 cm in their long axis and > 1.0 cm in their short axis before treatment must have decreased to ≤1.0 cm in their short axis after treatment. 2. The spleen and/or liver, if considered enlar ged before therapy on the basis of a physical examination or CT scan, should not be palpable on physical ex amination and s hould be considered normal size by imaging studies, and nodules related to lymphoma should disappear. However, determination of splenic involvement is not always reliable because a spleen considered normal in size may still contain lymphoma, whereas an enlarged spleen may reflect variations in anatomy, blood volume, the use of hematopoietic growth factors, or causes other than lymphoma. 3. If the bone marrow was involved by lymphoma before tr eatment, the infiltrate must have cleared on repeat bone marrow biopsy. The biopsy sample on which this determination is made must be adequate (with a goal of > 20 mm unilateral core). If the sample is indeterminate by morphology, it should be negative by immunohist ochemistry. A sample that is negative by immunohistochemistry, but demonstrates a small population of clonal lymphocytes by flow cytometry, will be considered a CR until data become av ailable demonstrating a clear difference in patient outcome. PR (Partial Remission) The designation of PR requires all of the following: 1. At least a 50% decrease in the sum of the product of the diameters (SPD) of up to 6 of the largest dominant nodes or nodal masses. These nodes or nodal masses s hould be selected according to all of the following: they s hould be clearly measurable in at least 2 perpendicular dimensions; if possible, they s hould be from dispar ate regions of the body; and they s hould include mediastinal and retroperitoneal areas of disease whenever these sites are involved. 2.